$IVST acquisition of H.P. Technologies last week, is the most recent. The Biotechnology & Health Sciences Division will launch upon its first completed transaction, expected this spring. The current pipeline of fourteen companies includes seven in the Commercial & Industrial Division, three in Biotechnology & Health Sciences. The others would mark entry into subsequent divisions. Eleven of the fourteen companies each generate greater annual revenue than Innovests current base, showing the business plan advancing to incrementally larger transactions. The company sees additions to, and subtractions from, the pipeline list regularly.